

Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting

LEXINGTON, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene will present data from multiple programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held from April 16 - 20, 2016 in New Orleans, LA.

Curis researchers will present data for its proprietary targeted cancer drug candidate, CUDC-907, an oral inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K). Curis' collaborator, Aurigene will present data from the immuno-oncology programs, including CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), as well as the PD-L1/ T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antagonist program. In addition, Aurigene will present data from the interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor program, including the lead compound CA-4948. Curis has exclusive licenses to CA-170 and CA-4948 under a collaboration agreement with Aurigene established in 2015.

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.

Poster Presentations

Date/Time: Wednesday, Apr 20, 2016, 8:00 AM - 12:00 PM

Session Title: Cellular Responses to Anticancer Drugs

Presentation Title: *Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies*

Abstract Number: 4634

Date/Time: Wednesday, Apr 20, 2016, 8:00 AM - 12:00 PM

Session Title: Immune Modulating Agents 2

Presentation Title: *Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy*

Abstract Number: 4861

Date/Time: Wednesday, Apr 20, 2016, 8:00 AM - 12:00 PM

Session Title: Novel Chemotherapies

Presentation Title: *Efficacy and safety of highly selective novel IRAK4 inhibitors for treatment of ABC-DLBCL*

Abstract Number: 4798

About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.

For More Information:

Mani Mohindru, Ph.D.

Senior Vice President, Corporate Strategy and Investor Relations

Curis, Inc.

617-503-6605

mmohindru@curis.com

Media Contact

David Schull

Russo Partners

(212) 845-4271

david.schull@russopartnersllc.com

<https://investors.curis.com/Curis-Announces-Presentation-of-Preclinical-Data-from-CUDC-907-CA-170-and-PD-L1-TIM-3-Antagonist-and-CA-4948-Programs-at-AACR-Annual-Meeting>